• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe newsletter
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: E-News

E-News

Fenofibrate dramatically shortens treatment time for severe Covid-19 patients – new clinical trials show

, 24 August 2021/in Corona News, E-News /by panglobal

Fenofibrate dramatically shortens treatment time for severe Covid-19 patients

 

A team at the Hebrew University of Jerusalem (HU) is reporting “astounding” results from a trial to check the efficacy of the lipid-lowering drug TriCor (fenofibrate) as a treatment for patients with severe Covid-19.

In earlier research, the team at HU, lead by Professor Yaakov Nahmias, reported that the new coronavirus causes abnormal accumulation of lipids, which are known to initiate severe inflammation in a process called lipotoxicity. Last year the team identified the lipid-lowering drug TriCor (fenofibrate) as an effective antiviral, showing it both reduced lung cell damage and blocked virus replication in the laboratory. These results have since been confirmed by several international research teams. An observational study carried out in multiple clinical centres in Israel was reported last October to support the original findings. The team then launched an interventional clinical study to treat severe Covid-19 patients at Israel’s Barzilai Medical Center with support from Abbott Laboratories.

Now, the HU team is reporting promising results from this trial – an investigator-initiated interventional open-label clinical study led by Nahmias and coordinated by Prof. Shlomo Maayan, Head of Infectious Disease Unit at Barzilai. In this single-arm, open-label study, 15 severe-hospitalized Covid-19 patients with pneumonia requiring oxygen support were treated. In addition to standard of care, the patients were given 145 mg/day of TriCor (fenofibrate) for 10 days and continuously monitored for disease progression and outcomes.

The findings were posted 12 August on Research Square and are currently under peer-review.

“The results were astounding,” said Nahmias. “Progressive inflammation markers, that are the hallmark of deteriorative Covid-19, dropped within 48 hours of treatment. Moreover, 14 of the 15 severe patients didn’t require oxygen support within a week of treatment, while historical records show that the vast majority severe patients treated with the standard of care require lengthy respiratory support,” he added.

These results are promising as TriCor (fenofibrate) was approved by the FDA in 1975 for long-term use and has a strong safety record.

“There are no silver bullets,” stressed Nahmias, “but fenofibrate is far safer than other drugs proposed to date, and its mechanism of action makes is less likely to be variant-specific.”

“All patients were discharged within less than a week after the treatment began and were discharged to complete the 10-day treatment at home, with no drug-related adverse events reported,” noted Maayan. “Further, fewer patients reported Covid-19 side effects during their 4-week follow-up appointment,” he added.

The investigators stressed that while the results were extremely promising, only randomized placebo-controlled studies can serve as basis for clinical decisions.

“We entered the second phase of the study and are actively recruiting patients”, explained Nahmias, noting that two Phase 3 studies are already being conducted in running South America, the United States (NCT04517396) and Israel (NCT04661930).

Reference

Metabolic Regulation of SARS-CoV-2 Infection. Yaakov Nahmias, et al. Research Square
DOI: https://doi.org/10.21203/rs.3.rs-770724/v1

https://interhospi.com/wp-content/uploads/sites/3/2021/08/covid_patient.jpg 1295 1417 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2021-08-24 16:53:202021-08-24 16:53:20Fenofibrate dramatically shortens treatment time for severe Covid-19 patients – new clinical trials show
people living with Post-Covid-19 Condition

Researchers start new investigation into Long Covid core outcome set

, 19 August 2021/in Corona News, E-News /by panglobal

Post Covid-19 Condition

 

 

The World Health Organization (WHO) recently called on countries to prioritise recognition, rehabilitation and research for the consequences of Covid-19, and the collection of standardised data on Long Covid. They proposed the term “Post Covid-19 Condition” should be used for people living with Long Covid.

A significant portion of people diagnosed with Covid-19 subsequently experience lasting symptoms including fatigue, breathlessness and neurological complications months after the acute infection. However, the evidence for this condition is limited and based on small patient cohorts with short-term follow-up.

Core outcome set

There is an urgent need for the development of a core outcome set (COS) to optimise and standardise clinical data collection and reporting across studies (especially clinical trials) and clinical practice for this condition. With this in mind, clinical research communities and people living with Post Covid-19 Condition have come together to respond to this emerging global healthcare crisis.

An international group of experts in COS development and Post Covid-19 Condition research and clinical practice have developed a programme of research together with WHO, ISARIC (International Severe Acute Respiratory and emerging Infection Consortium), and patient partners to develop a Post Covid-19 Condition COS.

People living with Post-Covid-19 Condition

This project, Post-Covid Condition Core Outcomes, will start by surveying people living with Post-Covid-19 Condition, assess what outcomes matter and build a plan in two phases. The first phase will focus on what outcomes should be measured and the second phase will focus on how to measure these outcomes.

Researchers aim to complete the first phase (what outcomes to measure) in the summer of 2021 and the second phase (how to measure these outcomes) in 2022.

This project follows the COMET (Core Outcome Measures in Effectiveness Trials) Initiative’s standards and has been registered on COMET’s COS registry.

This plan is being globally publicised in its early stages so that research and patient communities are aware, thereby potentially avoiding any unnecessary duplication of work, and to let researchers planning studies, especially clinical trials, and clinicians know the anticipated time frame of these recommendations.

https://interhospi.com/wp-content/uploads/sites/3/2021/08/headache_web.jpg 850 1134 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2021-08-19 12:52:112021-08-19 12:52:11Researchers start new investigation into Long Covid core outcome set

Fujifilm Irvine Scientific becomes sole worldwide distributor of Life Whisperer

, 11 August 2021/in E-News /by panglobal
D5 Human embryo

Day 5 human embryo

Fujifilm Irvine Scientific, a specialist in the development and manufacture of cell culture media and assisted reproductive technologies (ART), will become the sole worldwide distributor of Life Whisperer, the fertility arm of Presagen, a leader in Artificial Intelligence (AI) healthcare. Life Whisperer is a web-based software product that uses image-based analysis and AI to assist embryologists in the determination of embryo viability.

While many factors affect the success rate of in vitro fertilization (IVF), the conventional method of determining embryo viability by optical microscopy can be subjective, and critical morphological features that indicate embryo viability may be missed. The Life Whisperer software can aid this process by analysing high-resolution digital camera images taken of Day 5 embryos to assist in identifying embryo morphological features that correlate with uterine implantation potential. The AI algorithm produces a confidence score that objectively indicates an embryo’s implantation potential to produce an objective and standardized embryo viability score, thereby aiding embryologists in their effort to select embryos based on their likelihood of leading to a successful pregnancy.

“We view Presagen’s emerging suite of AI-enabled fertility workflow tools as a strong complement to our portfolio of ART product offerings and aligned with Fujifilm’s broader commitment to AI,” said Tim Mullane, president and chief operating officer, Fujifilm Irvine Scientific.

Steven Geimer, executive director of the Medical Business Unit, Fujifilm Irvine Scientific, commented: “We believe that AI-based ART technology can significantly impact the embryo selection process by providing an objective tool that embryologists can utilize as part of their process to help in the endeavour to increase a patient’s pregnancy potential.”

Presagen developed and implemented a healthcare information network that enables IVF clinics to access the AI tools through the secure and real-time transfer of clinical medical data. That networking platform underpinned the development of the Life Whisperer embryo viability tools.

Dr. Michelle Perugini, chief executive officer and co-founder, Presagen, said: “Life Whisperer tools were developed in collaboration with IVF clinics across the world. Additional fertility tools are under development which will be seamlessly integrated into our current AI platform. This application of AI offers embryologists an objective method of assessing embryo quality to help them increase the chance of a successful pregnancy for their patients. [1]”

  • The Life Whisperer embryo viability product is expected to be available this summer through Fujifilm Irvine Scientific and its existing distribution channels. The initial offering of the Life Whisperer embryo viability product will be authorized for sale in a number of countries across Europe and Asia Pacific. Additional countries are expected to be added as authorization for use by their respective regulatory agencies is received. It is not for sale in the USA. For more information, visit: irvinesci.com/lifewhisperer

Reference

  1. VerMilyea M, Hall JMM, Diakiw SM, et al. Development of an artificial intelligence-based assessment model for prediction of embryo viability using static images captured by optical light microscopy during IVF. Hum Reprod. 2020;35(4):770-784. https://doi.org/10.1093/humrep/deaa013
https://interhospi.com/wp-content/uploads/sites/3/2021/08/Human_embryo_web.jpg 720 722 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2021-08-11 08:15:122021-08-11 08:15:12Fujifilm Irvine Scientific becomes sole worldwide distributor of Life Whisperer
Hologic

Hologic acquires Mobidiag

, 11 August 2021/in E-News /by panglobal

Hologic

Hologic, a global leader in women’s health, has completed its acquisition of Mobidiag Oy, an innovator in near-patient, acute care molecular diagnostic testing, for an enterprise value of approximately US$808 million.

“Closing the acquisition of Mobidiag enables us to become a broader, more diversified global diagnostics leader,” said Jan Verstreken, group president, international at Hologic. “Together, we can accelerate development and adoption of Mobidiag’s innovative products globally and drive Hologic’s growth.”

Mobidiag provides near-patient, molecular diagnostic instruments and tests for acute care conditions including gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections. Its Amplidiag and Novodiag testing platforms deliver results in 50 minutes to two hours. The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing. Multiplexing enables multiple pathogens to be identified in a single sample, streamlining workflows for laboratories and providing rapid results to physicians.

https://interhospi.com/wp-content/uploads/sites/3/2021/08/Hologic_Logo.jpg 800 1280 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2021-08-11 07:34:142021-08-11 07:40:46Hologic acquires Mobidiag
no mRNA vaccine in breastmilk - JAMA study

Study finds no Covid-19 mRNA vaccine in breast milk

, 19 July 2021/in Corona News, E-News /by panglobal

no mRNA vaccine in breastmilk - JAMA study

A small study has found that no Covid-19 mRNA vaccine is present in human breastmilk following vaccination. The study by University of California San Francisco researchers provides early evidence that the vaccine mRNA is not transferred to the infant via breastmilk.

The study analysed the breastmilk of seven women after they received the Pfizer and Moderna mRNA vaccines and found no trace of the vaccine. The findings, although from a small sample, offer the first direct data of vaccine safety during breastfeeding and could allay concerns among those who have declined vaccination or discontinued breastfeeding due to concern that vaccination might alter human milk. The paper appears in JAMA Pediatrics.

The World Health Organization recommends people should continue breastfeeding following vaccination for Covid-19.

The Academy of Breastfeeding Medicine has said there is little risk of vaccine mRNA entering breast tissue or being transferred to milk, which theoretically could affect infant immunity.

“The results strengthen current recommendations that the mRNA vaccines are safe in lactation, and that lactating individuals who receive the Covid vaccine should not stop breastfeeding,” said corresponding author Stephanie L. Gaw, MD, PhD, assistant professor of Maternal-Fetal Medicine at UCSF.

The study was conducted from December 2020 to February 2021. The mothers’ mean age was 37.8 years and their children ranged in age from one month to three years. Milk samples were collected prior to vaccination and at various times up to 48 hours after vaccination.

Researchers found that none of the samples showed detectable levels of vaccine mRNA in any component of the milk.

The authors noted that the study was limited by the small sample size and said that further clinical data from larger populations was needed to better estimate the effect of the vaccines on lactation outcomes.

 

Reference

Golan Y, Prahl M, Cassidy A, et al. Evaluation of Messenger RNA From Covid-19 BTN162b2 and mRNA-1273 Vaccines in Human Milk. JAMA Pediatr. Published online July 06, 2021.
https://doi.org/10.1001/jamapediatrics.2021.1929

https://interhospi.com/wp-content/uploads/sites/3/2021/07/baby.jpg 1079 727 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2021-07-19 13:25:082021-07-19 13:25:08Study finds no Covid-19 mRNA vaccine in breast milk
child covid mask

Large observational study reports 50% of hospitalised Covid-19 patients develop a complication

, 16 July 2021/in Corona News, E-News, Featured Articles /by panglobal

Researchers warn complications may cause a substantial strain on health and social care in the coming years

 

covid-19

 

 

An observational study of more than 70,000 people in 302 UK hospitals finds that one in two people hospitalised with COVID-19 developed at least one complication. The new study, published in The Lancet [1], is the first to systematically assess a range of in-hospital complications, and their associations with age, sex and ethnicity, and their outcomes for the patients.

The authors say these complications are likely to have important short- and long-term impacts for patients, healthcare utilisation, healthcare system preparedness, and society amidst the ongoing COVID-19 pandemic. They also note that these complications are different to long COVID symptoms in patients with COVID-19 who were not hospitalised.

Risk to younger healthy adults

The authors say that complications in patients admitted to hospital with COVID-19 are high, even in young, previously healthy individuals – with 27% of 19-29 year olds and 37% of 30-39 year olds experiencing a complication. They also note that acute complications are associated with reduced ability to self-care at discharge – with 13% of 19-29 year olds and 17% of 30-39 year olds unable to look after themselves once discharged from hospital.

The study looked at cases between 17 January and 4 August 2020 before vaccines were widely available, and new variants of the virus had not arisen. However, the authors note that their findings remain relevant in dispelling suggestions that COVID-19 presents no risk to younger healthy adults, many of whom remain unvaccinated.

The authors warn that policymakers must consider the risk of complications for those who survive COVID-19, not just mortality, when making decisions around easing restrictions. The authors predict that COVID-19 complications are likely to cause significant challenges for individuals and for the health and social care system in the coming years. Policy makers and health-care planners should anticipate that large amounts of health and social care resources will be required to support those who survive COVID-19.

Chief Investigator and joint senior author of the study, Professor Calum Semple, University of Liverpool, UK, said: “This work contradicts current narratives that COVID-19 is only dangerous in people with existing comorbidities and the elderly. Dispelling and contributing to the scientific debate around such narratives has become increasingly important. Disease severity at admission is a predictor of complications even in younger adults, so prevention of complications requires a primary prevention strategy, meaning vaccination.”

Kidney, heart and lungs

Commenting on the research, joint senior author Professor Ewen Harrison from the University of Edinburgh, UK, said: “Patients in hospital with COVID-19 frequently had complications of the disease, even those in younger age groups and without pre-existing health conditions. These complications could affect any organ, but particularly the kidney, heart and lungs. Those with complications had poorer health on discharge from hospital, and some will have long-term consequences. We now have a more detailed understanding of COVID-19 and the risks posed, even to younger otherwise healthy people.”

He added: “Our review highlights some insightful patterns and trends that can inform healthcare systems and policy maker responses to the impacts of COVID-19. Our results can also inform public health messaging on the risk COVID-19 poses to younger otherwise healthy people at a population level, particularly in terms of the importance of vaccination for this group.”

Previous research on the impact of COVID-19 on patients has focussed on the numbers of deaths or on outcomes related to one specific organ system or health condition.

hospitalised covid-19 patient

Data collection

The new study assessed in-hospital complications in adults aged 19 years or over with confirmed or highly suspected SARS-CoV-2 infection leading to COVID-19 disease. Data were collected by nurses and medical students, and included the participants’ age, sex at birth, health measures when hospitalised, and comorbidities (such as asthma, chronic cardiac disease, chronic haematological disease, chronic kidney disease, chronic neurological disease, chronic pulmonary disease, HIV/AIDS, cancer, liver disease, obesity, rheumatological disorders, and smoking).

In addition, they collected data on the respiratory, neurological, cardiovascular, renal, gastrointestinal and systemic complications participants experienced while in hospital [2]. Complications were assessed at multiple timepoints until discharge or, if the patient was not discharged, 28 days after hospitalisation. The study also investigated the ability of patients to look after themselves when discharged from hospital.

80,388 patients were included in the study, but 7,191 were excluded due to duplicated medical records, as they were not eligible for the study, or because no data was collected on the compilations they experienced while in hospital.

Of the remaining 73,197 patients, 56% were men, 81% had an underlying health condition, 74% were of white ethnicity, and the average age of the cohort was 71 years. Almost one in three participants (32%, 23,092 of 73,197) in the study died.

Most common complications

Overall, complications occurred in 50% of all participants, including in 44% (21,784 of 50,105) of participants who survived.

The most common complications were renal (affecting almost one in four people, 24%, 17,752), respiratory (affecting around one in five people, 18%, 13,486), and systemic (affecting one in six, 16%, 11,895). However, cardiovascular complications were reported in around one in eight participants (12%, 8,973), and neurological (less than one in 20, 4%, 3,115), and gastrointestinal or liver (less than 11%, 7,901) complications were also reported. Specifically, acute kidney injury, probable acute respiratory distress syndrome, liver injury, anaemia, and cardiac arrhythmia were the most common complications.

The incidence of complications rose with increasing age, occurring in 39% (3,596 of 9,249) of 19-49 year olds, compared to 51% (32,771 of 63,948) of people aged 50 and older. Going up the age ranges, 27% of 19-29 year olds hospitalised with COVID-19 developed a complication, 37% of 30-39 year olds, 43% of 40-49 year olds, 49% of 50-59 year olds, 54% of 60-69 year olds, 52% of 70-79 year olds, 51% of 80-89 year olds, and 50% of people aged 90 or over (see Table 1).

Complications were more common in men compared with females, with males aged older than 60 years the most likely group to have at least one complication (women aged under 60 years: 37% [2,814 of 7,689] and men 49% [5,179 of 10,609]; women aged 60 years and over: 48% [11,707 of 24,288] and men 55% [16,579 of 30,416]).

People of white, South Asian, and East Asian ethnicities had similar rates of complications, but rates were highest in Black people (58% [1,433 of 2,480] in Black patients vs 49% [26,431 of 53,780] in white patients).

Self-care compromised

Following hospitalisation, 27% (13,309 of 50,105) of patients were less able to look after themselves than before COVID-19, and this was more common with older age, being male, and in people who received critical care. The association between having a complication and worse ability for self-care remained irrespective of age, sex, socioeconomic status, and which hospital someone received treatment in. Neurological complications were associated with the biggest impact on ability for self-care.

Strain on health and social care resources

Based on these rates, the authors say that policymakers and healthcare planners should anticipate that large amounts of health and social care resources will be required to support those who survive COVID-19. This includes adequate provision of staffing and equipment – for example, provision of follow-up clinics for those who have sustained in-hospital complications such as acute kidney injury or respiratory tract infection.

Dr Thomas Drake, co-author from the University of Edinburgh, UK, said: “Our research looked at a wide range of complications, and found that short-term damage to several organs is extremely common in those treated in hospital for COVID-19. These complications were common in all age groups, not just in older people or those with pre-existing health conditions. People who have complications will often need expert care and extra help to recover from their initial hospital admission. Our study shows it is important to consider not just death from COVID-19, but other complications as well. This should provide policy makers with data to help them make decisions about tackling the pandemic and planning for the future. We are still studying the participants in our study to understand what the long-term effects of COVID-19 on their health. The results from these ongoing studies will be particularly useful, as we found many people who survive COVID-19 and develop complications are from economically active age groups.”

Aya Riad, joint co-author from the University of Edinburgh, UK, said: “It is important that with the high risk of complications and the impact these have on people, that complications of COVID-19, not just death, are considered when making decisions on how best to tackle the pandemic. Just focussing on death from COVID-19 is likely to underestimate the true impact, particularly in younger people who are more likely to survive severe COVID-19.”

The authors note that around 85% of participants had a positive SARS-CoV-2 RT-PCR test, and patients who did not have a positive test recorded similar or slightly lower rates of in-hospital complications.

Study limitations

They also note some limitations, including that the data does not provide a long-term picture, and that the timings of complications and patients quality of life were not studied. In addition, the complications in the study were predefined and not specific to COVID-19, so may underestimate some areas as these were added later. In addition, as it was inappropriate to subject patients to numerous tests, patients did not undergo additional tests for complications, and the authors say that the true burden of complications is likely to be higher.

References

[1] Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. The Lancet.

[2] Data were collected on organ-specific complications including complex respiratory (bacterial pneumonia, acute respiratory distress syndrome [ARDS], empyema, pneumothorax, and pleural effusion), neurological (meningitis, encephalitis, seizure, and stroke), cardiovascular (thromboembolism, heart failure, myocarditis, endocarditis, arrhythmia, cardiomyopathy, myocardial ischaemia, and cardiac arrest), acute kidney injury, gastrointestinal (acute liver injury, pancreatitis, and gastrointestinal haemorrhage), and other systemic complications (coagulopathy, disseminated intravascular coagulation, anaemia, and bloodstream infection).

https://interhospi.com/wp-content/uploads/sites/3/2021/07/child-5770618_1920.jpg 1282 1920 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2021-07-16 09:16:092021-07-16 09:17:29Large observational study reports 50% of hospitalised Covid-19 patients develop a complication

Knowledge about the human transcriptome assembled in comprehensive RNA-atlas

, 15 July 2021/in E-News /by panglobal

Together with Baylor College of Medicine and the world’s leading sequencing company, Illumina, researchers at Ghent University have built one of the most comprehensive catalogues of the human transcriptome ever.

Read more
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2021-07-15 14:06:422021-07-15 14:06:42Knowledge about the human transcriptome assembled in comprehensive RNA-atlas

Stents inspired by papercutting art designed to deliver drugs to GI tract

, 15 July 2021/in E-News /by panglobal

Inspired by kirigami, the Japanese art of folding and cutting paper to create threedimensional structures, MIT engineers and their collaborators have designed a new type of stent that could be used to deliver drugs to the gastrointestinal tract, respiratory tract, or other tubular organs in the body.

Read more
https://interhospi.com/wp-content/uploads/sites/3/2021/07/kirigami_stent.jpg 1160 1484 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2021-07-15 13:38:532021-07-15 13:39:16Stents inspired by papercutting art designed to deliver drugs to GI tract

EU establishes new regulations for medical devices

, 15 July 2021/in E-News /by panglobal

As of 26 May this year, new EU rules on medical devices (MDR) entered into application, establishing a modern and more robust regulatory framework to protect public health and patient safety. The new rules start applying after a one-year postponement due to the unprecedented challenges of the Covid-19, addressing the need for an increased availability […]

Read more
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2021-07-15 13:10:572021-07-15 13:10:57EU establishes new regulations for medical devices

Philips, Elekta deepen strategic partnership in precise, individualized oncology care

, 15 July 2021/in E-News /by panglobal

Royal Philips and Elekta have signed agreements to deepen their existing strategic partnership to advance comprehensive and personalized cancer care through precision oncology solutions.

Read more
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2021-07-15 13:07:022021-07-15 13:07:02Philips, Elekta deepen strategic partnership in precise, individualized oncology care
Page 49 of 231«‹4748495051›»

Latest issue of International Hospital

April 2024

4 July 2025

Everdrone expands world-first medical emergency drone network in Sweden

4 July 2025

Wireless implant breakthrough offers personalised chronic pain relief

3 July 2025

EEG-powered brain computer interface enables finger-level robotic hand control

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription